MESTEROLONE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H32O2
Molecular Weight	304.4669
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)C[C@H](C)[C@]34C

InChI

InChIKey=UXYRZJKIQKRJCF-TZPFWLJSSA-N

InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H32O2
Molecular Weight	304.4669
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Mesterolone is an androgen receptor agonist which was developed for hormone replacement therapy in males suffering from androgen deficiency and related disorders. Mesterolone is known under the name Proviron. The drug is also used by bodybuilders and athletes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen receptor 42	Agonist 2,678

Conditions

Condition	Modality	Highest Phase	Product
Infertility 14	Curative	Approved 8,429	PROVIRON
Hypogonadism 28	Palliative	Approved 8,429	PROVIRON
Potency disturbances 1	Curative	Approved 8,429	PROVIRON
Androgen deficiency 1	Primary	Approved 8,429	PROVIRON

Doses

Doses

Show entries

Dose	Population	Adverse events
150 mg 1 times / day steady-state, oral Studied dose	unhealthy, ADULT
450 mg 1 times / day steady-state, oral Studied dose	unhealthy, ADULT

Showing 1 to 2 of 2 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Mass spectrometry of steroid glucuronide conjugates. II-Electron impact fragmentation of 3-keto-4-en- and 3-keto-5alpha-steroid-17-O-beta glucuronides and 5alpha-steroid-3alpha,17beta-diol 3- and 17-glucuronides.	2001 Sep	11599078
Oligospermia due to partial maturation arrest responds to low dose estrogen-testosterone combination therapy resulting in live-birth: a case report.	2002 Dec	12508135
Morphological changes in murine skeletal muscle in response to exercise and mesterolone.	2010	19854955
Successful treatment of methimazole-induced severe aplastic anaemia in a diabetic patient with other co-morbidities.	2010 Dec 20	22802368
Effect of high intensity aerobic exercise and mesterolone on remodeling of Achilles tendon of C57BL/6 transgenic mice.	2010 Feb	19902256

Showing 1 to 5 of 5 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

The tablets should be swallowed whole with some liquid. The recommended doses are: 1 tablet (25 mg) 3 times/day (reduced efficiency and potency disturbances), 1 tablet 2-3 times/day (Infertility), 1-2 tablets 3 times/day (for development of secondary male sex characteristics in hypogonadism).

Route of Administration: Oral

In Vitro Use Guide

Mesterolone showed activation effect on mutant androgen receptor (expressed in HeLa and COS-7 cells) at doses 0.1–300 nM.